Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amag Pharmaceuticals (AMAG)

Amag Pharmaceuticals (AMAG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 317,058
  • Shares Outstanding, K 33,910
  • Annual Sales, $ 474,000 K
  • Annual Income, $ -65,760 K
  • 60-Month Beta 0.42
  • Price/Sales 0.98
  • Price/Cash Flow 6.10
  • Price/Book 0.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.61
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.76
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -1.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.21 +1.52%
on 01/27/20
13.00 -28.08%
on 01/03/20
-3.18 (-25.38%)
since 12/27/19
3-Month
8.89 +5.17%
on 11/08/19
13.53 -30.89%
on 10/28/19
-2.91 (-23.74%)
since 10/25/19
52-Week
6.81 +37.30%
on 08/07/19
17.13 -45.42%
on 02/05/19
-7.10 (-43.16%)
since 01/25/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.35 (-2.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.35 (-2.91%)
Watch for Amag Pharmaceuti to Potentially Rebound After Falling 9.62% Yesterday

Amag Pharmaceuti (NASDAQ:AMAG) traded in a range yesterday that spanned from a low of $10.55 to a high of $11.59. Yesterday, the shares fell 9.6%, which took the trading range below the 3-day low of...

AMAG : 9.35 (-2.91%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.35 (-2.91%)
AMAG Pharmaceuticals (AMAG) Upgraded to Buy: Here's Why

AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMAG : 9.35 (-2.91%)
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

AMAG : 9.35 (-2.91%)
EBS : 53.54 (-4.43%)
AMRN : 19.66 (-2.77%)
BOLD : 59.97 (-0.02%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMAG : 9.35 (-2.91%)
AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update

Initiating CEO transition plan

AMAG : 9.35 (-2.91%)
AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the 38 Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:30 a.m. Pacific Time (12:30...

JPM : 132.03 (-0.84%)
AMAG : 9.35 (-2.91%)
AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research

As part of the company's ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded four...

AMAG : 9.35 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AMAG with:

Business Summary

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the...

See More

Key Turning Points

2nd Resistance Point 10.07
1st Resistance Point 9.71
Last Price 9.35
1st Support Level 9.10
2nd Support Level 8.85

See More

52-Week High 17.13
Fibonacci 61.8% 13.19
Fibonacci 50% 11.97
Fibonacci 38.2% 10.75
Last Price 9.35
52-Week Low 6.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar